HTG2014-Section-Header-publications

Categories

Filter by Topics

478P TA-ness ADCC Gene Alteration adolescents ALK alzheimer's Angiogenesis Anti-TNF Alpha Therapy antiEGFR Apoptosis apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 benign Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Bladder Cancer Blood Brain Breast Cancer Breast milk Burkitt lymphoma cancer genetics Cancer Genomics Cardiovascular Disease Castleman Disease CD3 CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma GEIS gene expression Gene Expression Gene Expression Profiling gene expression profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors HCC Head and Neck Cancer Heart hepatocellular carcinoma HER-2 HER2 HER2- Histone Deacetylase Inhibitors HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay Ibrutinib ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC IMMUNOSARC Immunotherapy Inflammation Integrins inverted papilloma ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoma lymphomas machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab Non-alcoholic fatty liver disease non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer PALLET PALOMA-2 Pancreas Pancreatic Cancer Paralysis Parkinson's Disease Pathogenesis Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PENELOPE-B PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison PMAIP1 Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium squamous cell carcinoma Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer tislelizumab TMB tomentosin Toxicity TP53 mutation Transcriptome Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue Zanubrutinib

2018

2017

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312

PMID: 28131785

View External Link

Page last updated June 23, 2022